FL-NCIPHER-SECURITY
17.9.2019 09:03:05 CEST | Business Wire | Press release
nCipher Security, an Entrust Datacard company , announces nShield as a Service , a cloud-based hardware security module (HSM) service that allows organizations to protect sensitive data and applications and helps meet compliance mandates – simply and efficiently, using on-demand cryptography.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005391/en/
“Organizations embracing cloud-first strategies require cloud-first encryption,” said Peter Galvin, vice president of strategy, nCipher Security. “This means remote, automated management at scale, and flexible access control both in the cloud and onsite. nShield as a Service makes it easy to adopt a secure, multi-cloud encryption strategy using the same nShield HSMs organizations deploy onsite today.”
nShield as a Service is ideal for cloud-first strategies, selective cloud migration, or adding HSM capacity to handle workload spikes. The customer experience is consistent and familiar – users interact with the cloud-based nShield® HSMs in the same way as with nShield appliances in their own data centers. And customers utilizing nCipher’s unique secure execution environment to run sensitive application code within a secure FIPS-validated boundary now have that same opportunity using cloud-based as well as on premises HSMs.
Using nShield as a Service, customers can:
- implement Bring Your Own Key and Host Your Own Key solutions with a trusted third party service
- maintain full control over key material and maintain separation of data from the encryption keys
- extend cloud-based cryptography and key management across multiple clouds
- implement secure code execution for cloud-based workloads
- integrate with third party applications in the cloud
“The nShield as a Service launch highlights the synergies we’ve gained since becoming an Entrust Datacard company in June,” Galvin said. “We were able to accelerate and enhance nShield as a Service by combining our HSM and cryptography expertise with Entrust Datacard’s experience in data centers, cloud services and HSM operations. The result is a powerful HSM as a service solution that complements the company’s cloud-based PKI and IoT security solutions.”
“Encryption is a powerful tool,” said Robert Westervelt, Research Director, Security Products, IDC. “Delivering it easily across distributed infrastructure can be very effective in protecting data and applications against cyberattacks. Solutions such as nShield as a Service allow even the largest organizations to secure their public cloud workloads with all the conveniences of software-as-a-service offerings. Now, there are no excuses for not using encryption in the cloud.”
How nShield as a Service works
nShield as a Service uses nShield HSMs to generate, access and protect cryptographic key material separately from sensitive data. All nShield HSMs are managed through nCipher’s unique Security World key management architecture that spans cloud-based and on premises HSMs. This lets customers efficiently scale HSM operations while retaining control of their key material, even if they change their cloud service provider.
Organizations can utilize nShield as a Service to supplement or replace on premises HSMs, while keeping the benefits of HSM ownership. The subscription model lets enterprises budget predictably, manage capacity, reduce data center footprint and decrease time spent on routine maintenance and monitoring.
Customers seeking cloud-first solutions can work with market-leading cybersecurity and infrastructure vendors in nCipher’s nFinity Strategic Technology Partner program , including F5, IBM, Micro Focus Voltage, Red Hat and Venafi (see quote sheet below). Applications include SSL/TLS, code signing, data and database encryption and more.
nCipher Security nFinity Strategic Technology Partners talk about nShield as a Service:
F5
“F5 has deep experience in application delivery and security services and helps customers protect their critical applications, ensuring they are safe, secure, and available. The launch of nShield as a Service from nCipher Security gives F5 customers enhanced security choices with the ability to achieve data sovereignty on a subscription-based model. Shifting security from a capital to an operational expenditure enables greater flexibility and cost-effectiveness for organizations,” said John Morgan, VP & GM of Security at F5 Networks.
Rick Robinson, WW Offering Manager, Encryption and Key Management, IBM Security:
“As enterprises increasingly migrate business processes to the cloud, security continues to be a major concern. Ensuring that critical applications and their underpinning cryptographic keys can be protected and managed throughout their lifecycle is vital. The launch of nShield as a Service from nCipher Security gives our joint customers greater choice and the ability to have subscription-based data sovereignty,” said Rick Robinson, WW Offering Manager, Encryption and Key Management, IBM Security.
Micro Focus Voltage
“Data is one of the most abundant and valuable assets for an organization today,” said Reiner Kappenberger, Director Product Management, Voltage Data Security at Micro Focus. “However, without reliable ways to protect data at rest, in motion, and in use, these very assets can become liabilities. As Voltage SecureData customers increasingly migrate storage and workloads to cloud-based environments, they are looking to establish an HSM-based root of trust in the cloud that can maintain the highly available, highly performant data-centric solution they currently enjoy. nShield as a Service from nCipher Security, through its support of Voltage SecureData’s innovative Stateless Key Management, enables Micro Focus to offer its customers continuing relief from the burden of traditional key management in both hybrid and zero data center cloud deployments.”
Red Hat
“As a long-standing nCipher Security nFinity technology partner and the world’s leading provider of open source solutions, Red Hat is committed to providing customers with more choices to enhance. nShield as a Service from nCipher will offer expanded choice to our customers in how they pursue IT security to better protect the underlying cryptographic keys that help to secure Red Hat Certificate System and Red Hat OpenStack Platform deployments across the hybrid cloud,” said Keith Basil, Senior Principal Product Manager at Red Hat.
Venafi
“As the leader in machine identity protection, Venafi welcomes the launch of the new nShield as a Service capability from nCipher Security,” said Kevin Bocek, VP Security Strategy and Threat Intelligence at Venafi. “With the number of machines growing exponentially, and the definition of machines expanding to include everything from containers in Kubernetes clusters running in cloud to embedded IoT devices that will be deployed for the next 20 years, securing machine identities is critical for every business and government. The new nShield as a Service delivers the same robust root of trust that customers have come to depend on with on-premises nShield HSMs, adding a subscription-based security alternative that is easy to use, flexible, and cost-effective for organizations no matter their size. This is an exciting development that will help fast DevOps and security teams move at cloud speed to secure TLS and code signing keys certificates.”
About nCipher Security
nCipher Security, an Entrust Datacard company , is a leader in the general-purpose hardware security module (HSM) market, empowering world-leading organizations by delivering trust, integrity and control to their business-critical information and applications. Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency – it also multiplies the security risks. Our cryptographic solutions secure emerging technologies such as cloud, IoT, blockchain, and digital payments and help meet new compliance mandates. We do this using our same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business-critical applications, ensure the integrity of your data and put you in complete control – today, tomorrow, always. www.ncipher.com
Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005391/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
